Psychiatry Service, University Hospital of Salamanca, Salamanca.
Psychiatry Clin Neurosci. 2014 Feb;68(2):127-32. doi: 10.1111/pcn.12110. Epub 2013 Oct 31.
This study investigated whether biochemical parameters add predictive information concerning risk for weight gain associated with treatment with atypical antipsychotics (AP) to that provided by baseline weight.
Weight changes were assessed in 25 patients with schizophrenia after 3-6 months of treatment. These patients were started on AP monotherapy owing to a first psychotic episode or resumed treatment after at least a 6-month period of abandonment. Anthropometric and biochemical data were collected and analyzed as predictors of early weight change.
The baseline biochemical and anthropometric data were not significantly higher in the patients than in the healthy participants. During follow up, the patients had significant increases in body mass index and total cholesterol and apolipoprotein B level. The baseline weight and leptin level were predictive of weight gain during follow up, with an inverse association in both cases.
Baseline weight and leptin level may help to assess the risk of early weight gain with AP.
本研究旨在探讨生化参数是否能为与使用非典型抗精神病药物（AP）相关的体重增加风险提供预测信息，从而补充基线体重所提供的信息。
对 25 名精神分裂症患者在接受 3-6 个月治疗后的体重变化进行评估。这些患者由于首次出现精神病发作而开始接受 AP 单药治疗，或者在至少 6 个月的停药期后重新开始治疗。收集并分析了人体测量学和生化数据，以作为早期体重变化的预测因子。
与健康参与者相比，患者的基线生化和人体测量学数据并没有显著更高。在随访期间，患者的体重指数、总胆固醇和载脂蛋白 B 水平显著增加。基线体重和瘦素水平可预测随访期间的体重增加，两者均呈负相关。
基线体重和瘦素水平可能有助于评估使用 AP 时早期体重增加的风险。
